27 Sep, 2021

Genor Biopharma included in the Chinese Antibody Drug Companies Innovation TOP 30

 

With a focus on innovation and investment, the China BioMed Innovation and Investment Conference was held in Suzhou from September 25-27, 2021. During the conference, the 2020 Chinese Biopharma Companies Innovation TOP 100 Series Lists were officially released.  Genor Biopharma was included in the Chinese Antibody Drug Companies Innovation TOP 30.

 

In March 2021, personnel in charge of MENET and experts from the Expert Committee of Chinese Biopharma Companies Innovation TOP 100 visited Genor Biopharma. The experts were deeply impressed by the company’s insistence on innovation ability, 10+ years of continuous practice of CMC (Chemistry, Manufacturing and Controls), dual R&D centers in China and the United States for the development and optimization of highly differentiated bispecific/multi-specific antibodies, and the perfect preparation for commercial operation.

 

In particular, the cutting-edge bispecific and multi-specific discovery platform (Antibody Therapeutics Inc.) engineers novel and highly differentiated therapeutic antibody candidates with display technology, computer-aided design and site mutagenesis. This enables Genor Biopharma to have a strong bispecific/multi-specific antibodies pipeline. Among the six global rights FIC/BIC bispecific/multi-specific antibodies listed as Late Breaking Abstracts at AACR 2021, were CD20/CD3 (GB261), PD-L1/CD55 (GB262), EGFR/C-MET/C-MET (GB263T), and Claudin 18.2/CD3 (GB264).

 

GB261 has received IND approval in Australia, and the other five preclinical molecules are in the IND enabling phase. They are expected to be submitted to IND between the second half of 2021 and the end of 2022. In addition, six global FICs are in the drug molecular development stage, and are expected to be submitted to IND in 2023. Their aim is to tackle intractable tumors.

 

 

2020 Chinese Biopharma Companies Innovation TOP 100 Series Lists

The innovation evaluation index of this series was grouped into four dimensions – innovation input, innovation achievements, intellectual property and innovation drive – with 11 index systems. Innovative drug companies were evaluated comprehensively based on public data from their annual reports, CDE assessment data, third-party patent statistics agencies, MENET database, etc.